Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Net Income towards Common Stockholders (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Net Income towards Common Stockholders for 6 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 139.05% to $19.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$140.1 million through Dec 2025, up 12.9% year-over-year, with the annual reading at -$140.1 million for FY2025, 12.9% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was $19.4 million at 4D Molecular Therapeutics, up from -$56.9 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $19.4 million in Q4 2025, with the low at -$56.9 million in Q3 2025.
  • Average Net Income towards Common Stockholders over 5 years is -$29.0 million, with a median of -$28.4 million recorded in 2022.
  • The sharpest move saw Net Income towards Common Stockholders crashed 327.49% in 2024, then skyrocketed 139.05% in 2025.
  • Over 5 years, Net Income towards Common Stockholders stood at -$25.1 million in 2021, then decreased by 9.15% to -$27.4 million in 2022, then fell by 17.91% to -$32.3 million in 2023, then crashed by 53.86% to -$49.7 million in 2024, then skyrocketed by 139.05% to $19.4 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at $19.4 million, -$56.9 million, and -$54.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.